Rahul Ray, PhD

Professor, Medicine

Rahul Ray
75 E. Newton St


Expertise includes: Nanomedicine; Cancer drug therapeutics; Targeted drug delivery.

Other Positions

  • Research Professor, Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine
  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
  • Graduate Faculty (Primary Mentor of Grad Students), Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
  • Boston Medical Center


  • Washington State University, PhD
  • University of Calcutta, MSc
  • Presidency College, BSc


  • Published on 7/21/2016

    Gari HH, DeGala GD, Ray R, Lucia MS, Lambert JR. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion. Cancer Lett. 2016 Oct 01; 380(2):505-12. PMID: 27452906.

    Read at: PubMed
  • Published on 3/29/2016

    Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget. 2016 Mar 29; 7(13):15757-71. PMID: 26909599.

    Read at: PubMed
  • Published on 10/1/2014

    Gari HH, Ray R, Lucia S, Porter CC, Gearheart CM, Fosmire S, Degala GD, Fan Z, Ru Y, Thor AD, Lambert JR. Cancer Research. Abstract 4604: PTP4A3 is oncogenic and modulates triple negative breast cancer growth. 2014; 74(19):4604.

    Read at: Custom
  • Published on 9/13/2013

    Datta-Mitra A, Mitra A, Ray R, Raychaudhuri SP, Kundu-Raychaudhuri S. 1,25-Dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K/Akt/mTOR signaling cascade. Int Immunopharmacol. 2013 Nov; 17(3):744-51. PMID: 24036370.

    Read at: PubMed
  • Published on 1/11/2013

    Datta Mitra A, Raychaudhuri SP, Abria CJ, Mitra A, Wright R, Ray R, Kundu-Raychaudhuri S. 1a,25-Dihydroxyvitamin-D3-3-bromoacetate regulates AKT/mTOR signaling cascades: a therapeutic agent for psoriasis. J Invest Dermatol. 2013 Jun; 133(6):1556-64. PMID: 23314787.

    Read at: PubMed
  • Published on 3/1/2012

    Ray R, Banks M, Abuzahra H, Eddy VJ, Persons KS, Lucia MS, Lambert JR, Holick MF. Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model. Anticancer Res. 2012 Mar; 32(3):727-31. PMID: 22399584.

    Read at: PubMed
  • Published on 3/1/2012

    Sadler S, Ray R, Jones GB. Designed PDT agents: Synthesis and biological evaluation of steroid-porphyrin conjugates. 2012.

  • Published on 6/1/2011

    Sadler S, Persons KS, Jones GB, Ray R. Internalization of a C17a-alkynylestradiol-porphyrin conjugate into estrogen receptor positive MCF-7 breast cancer cells. Bioorg Med Chem Lett. 2011 Aug 1; 21(15):4638-41. PMID: 21704522.

    Read at: PubMed
  • Published on 2/18/2011

    Ray R, Lambert JR. 1a,25-Dihydroxyvitamin D3-3ß-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of action. Bioorg Med Chem Lett. 2011 Apr 15; 21(8):2537-40. PMID: 21392983.

    Read at: PubMed
  • Published on 1/1/2011

    Ray R, Lambert JR, Persons KS, Eddy VJ. Cancer Research. Abstract 5533: Anti-proliferative and anti-tumor effects of a novel vitamin D derivative, either alone or in a liposomal formulation in malignancies of kidney, pancreas and prostate. 2011; 70(8):5533.

    Read at: Custom

View 66 more publications: View full profile at BUMC

View all profiles